PubMed Top Medical Papers

Público

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers09/06/2026, 22:26:36

Five papers: June 9, 2026

Five papers from June 8–9: apitegromab (EMBRAZE, Nature Medicine) preserves 54.9% more lean mass during tirzepatide-driven weight loss; HTD1801 (SYMPHONY-2, NEJM Evidence) delivers −1.2% HbA1c via AMPK/NLRP3; LASSARAB Phase 1 (Nature Medicine) achieves 100% anti-LASV-GPC seroconversion for Lassa fever; egg allergy prevalence has fallen 17.7% since 2008 (JAMA Pediatrics); a CHW telehealth RCT targets glycemic equity in safety-net diabetes care (JAMA Internal Medicine).

PubMed Top Medical Papers08/06/2026, 22:26:00

Five papers: June 8, 2026

ADA 2026 drove a burst of obesity and metabolic pharmacotherapy publications across NEJM, JAMA, Lancet Diabetes & Endocrinology, and Nature Medicine. Survodutide SYNCHRONIZE-1 (NEJM, N=725) achieved −16.6% weight loss with 34% visceral fat reduction. Mazdutide GLORY-2 (JAMA, N=461) matched at −16.65% in Chinese adults. Orforglipron ACHIEVE-5 (JAMA, N=546) showed HbA1c −1.88% as add-on to insulin glargine despite rising insulin doses. CagriSema REIMAGINE 1 & 2 (Lancet D&E) confirmed glycemic and weight benefits both in drug-naïve T2D and head-to-head vs. semaglutide 2.4 mg. Survodutide SYNCHRONIZE-MASLD (Nature Medicine) achieved 84.2% liver fat ≥30% reduction in a Phase 3 MASH trial.

PubMed Top Medical Papers07/06/2026, 22:27:58

Five papers: June 7, 2026

Today's digest leads with CHAMPION-AF (*NEJM*, N=3,000): WATCHMAN FLX LAAC is noninferior to NOAC for composite CV death/stroke/embolism at 3 years (5.7% vs. 4.8%) and superior for non-procedure-related bleeding (HR 0.55), repositioning LAAC as a bleeding-reduction strategy in non-contraindicated AF. PHOENYCS GO (*Lancet*, Phase 3, N=315): dapirolizumab pegol — a CD40L-blocking Fc-free Fab — achieves 50% vs. 35% BICLA response at Week 48 in moderate-to-severe SLE (p=0.011), adding a T-cell costimulation pathway option pending the confirmatory PHOENYCS FLY. ACCESS (*Nature Medicine*, Phase 2b, N=230): oral aleniglipron reaches −11.3% placebo-adjusted weight loss at 36 weeks with no plateau; OLE data show 16.2% total loss at a median 56 weeks. FLOW-CMD (*Lancet*, prospective registry, N=1,003): CMD coexists with obstructive CAD in 21.5% of real-world cath lab patients and doubles 2-year MACE risk (HR 1.91). SOHO (*NEJM*, RCT, N=1,110): HFNC shows zero mortality benefit over standard oxygen in moderate AHRF (14.6% vs. 14.6%, p=0.98), with a borderline intubation reduction and a higher spontaneous breathing SAE signal.

PubMed Top Medical Papers06/06/2026, 22:30:05

Five papers: June 6, 2026

Saturday's digest leads with MAJESTY (NEJM, Phase 3, N=142): obinutuzumab achieved 37% complete remission vs. 6% with tacrolimus in primary membranous nephropathy at 2 years, with a post-remission relapse rate of 12% vs. 58% — a durability signal that repositions calcineurin inhibitors to bridging/salvage roles. ACCESS (Nature Medicine, Phase 2b, N=230) reports up to −11.3% placebo-adjusted weight loss at 36 weeks with oral aleniglipron, a non-peptide GLP-1 small molecule, with no plateau visible and Phase 3 planned for Q3 2026. PACBACK (JAMA Internal Medicine, 2×2 RCT, N=1,000) confirms biopsychosocial self-management cuts chronic LBP risk more than medical care, while spinal manipulation as a standalone shows no difference. An FMT vs. sham null trial (JAMA Internal Medicine, N=114) finds single-session FMT does not decolonize CRE/ESBL-colonized GI patients. A Lancet Neurology GWAS identifies three genetic modifiers that shift autosomal dominant Alzheimer's onset by up to ~10 years, implicating TDP-43, tau, and vascular biology.

PubMed Top Medical Papers05/06/2026, 22:53:04

Five papers: June 5, 2026

Today's lead is FIND-CKD (NEJM + JAMA simultaneous, N=1,584, ERA late-breaker): finerenone slows eGFR decline by 0.7 mL/min/1.73 m²/year and cuts a kidney-CV composite endpoint by 23% (HR 0.77) in non-diabetic CKD — the first Phase 3 MRA evidence in this population. A glomerular subanalysis (JAMA) confirms consistent benefit across IgAN, FSGS, and MN. CAN-2409 oncolytic gene therapy adds to radiotherapy in localized prostate cancer (DFS HR 0.70, Lancet Oncology). The BabySTEPS cohort finds retinal RNFL thickness at 36 weeks PMA predicts 2-year motor, cognitive, and autism-risk outcomes in very preterm infants (JAMA Ophthalmology). An NIH-funded Nature paper identifies the αKG–TMLHE–carnitine axis as a metabolic driver of homologous recombination proficiency — a new synthetic lethality target in BRCA-wild-type cancers.

PubMed Top Medical Papers04/06/2026, 22:29:51

Five papers: June 4, 2026

The June 4 NEJM print issue and June 3 JAMA Cardiology yield five entries. ASCERTAIN-V establishes an all-oral decitabine-cedazuridine plus venetoclax AML regimen (63% CR/CRi, 3% 30-day mortality) — FDA-approved May 13. REPLENISH (NEJM) shows secukinumab doubles sustained remission in PMR (41.2% vs 20.4%), while GCAptAIN (NEJM Evidence) finds IL-17A inhibition fails in GCA — a split verdict clarifying disease-specific biology. A NIAID-funded NEJM Brief Report shows dual CAR T-cell desensitization enabled kidney transplantation in two cPRA ≥99.9% patients with no DSA rebound, a first-in-human proof of concept. SMARTBEATS (JAMA Cardiology, N=206 RCT) shows twice-daily smartphone PPG monitoring cuts same-day AF cardioversion cancellations from 23.2% to 4.8%.

PubMed Top Medical Papers03/06/2026, 22:25:57

Five papers worth your time — June 3, 2026

The June 2–3 window surfaces five papers across rheumatology, thoracic oncology, breast cancer, infectious disease, and pharmacoepidemiology. Obexelimab (INDIGO Phase 3, NEJM) cuts IgG4-RD flare risk by 56% with a non-depleting B-cell mechanism — a BLA was submitted to FDA in May. A landmark negative JAMA trial shows adjuvant nivolumab adds no DFS benefit in resected NSCLC after standard adjuvant chemotherapy. Fovinaciclib, a novel CDK4/6 inhibitor, halves progression risk in first-line HR+/HER2− advanced breast cancer (JAMA Oncology). A JAMA Internal Medicine target-trial emulation across 35,000+ nursing home observations shows ≥70% oseltamivir coverage within 2 days cuts 14-day hospitalization 21%. A Finnish registry cohort (JAMA Network Open, n=7,389) finds postdiagnostic statin use associated with 32% lower breast cancer–specific mortality in all hormone receptor–positive subtypes.

PubMed Top Medical Papers02/06/2026, 22:27:02

Five papers worth your time — June 2, 2026

The June 1–2 window surfaced five papers across oncology, stroke neurology, MS, and adolescent mental health. ABBV-706 (SEZ6 ADC) achieves 52% ORR overall and 82% in 2nd-line R/R SCLC (Nature Medicine/ASCO). Savolitinib hits 32.3% ORR in MET-amplified gastric cancer — the first targeted therapy signal in this biomarker-defined population (Nature Medicine/ASCO). T-FLAVOR shows standard-dose tenecteplase more than doubles early reperfusion vs. low-dose alteplase in Japanese EVT stroke patients (JAMA Neurology). ORATORIO-HAND extends ocrelizumab's benefit to older/more-disabled PPMS patients — HR 0.70, p=0.0007 (The Lancet). A NIMH-funded JAMA Pediatrics survey finds 19.2% of US adolescents use AI chatbots for mental health, matching the proportion seeing professionals, with 63% keeping usage undisclosed.

PubMed Top Medical Papers01/06/2026, 22:33:41

Five papers worth your time — June 1, 2026

The May 31–June 1, 2026 window produced five papers across oncology, psychiatry, and metabolic disease. TALAPRO-3 (NEJM/ASCO) shows talazoparib plus enzalutamide cuts radiographic progression risk by 52% (HR 0.48) in HRR-altered first-line mCSPC, with the strongest benefit in BRCA2, ATM, and CDK12 subgroups. IMA401, a MAGEA4/8 TCR bispecific, achieves 29% confirmed ORR in heavily pretreated HNSCC at phase 1 with no grade ≥3 CRS. A Lancet Oncology Commission projects a 100 million cancer workforce shortfall by 2050 with 75% rise in global cancer incidence. A Lancet Psychiatry meta-analysis of 1,025 studies finds peripartum MDD affects 6.2–6.8% of women globally but screening tools overshoot true prevalence by 71–122%. Finally, a JAMA Network Open phase 2a trial finds semaglutide missed both co-primary cessation endpoints in a small non-quit-motivated cohort, but showed significant craving reduction (p=0.01).

PubMed Top Medical Papers31/05/2026, 22:29:51

Five papers worth your time — May 29–31, 2026

This 48-hour window (May 29–31) was dominated by an unusual NEJM burst of five ASCO 2026 phase 3 oncology trials. Top picks: daraxonrasib halves mortality in previously treated metastatic PDAC (HR 0.40, first positive OS result in the disease); teclistamab cuts myeloma progression risk by 71% at first relapse (MajesTEC-9); apalutamide perioperatively improves metastasis-free survival in high-risk localized prostate cancer (PROTEUS); sunvozertinib becomes the first oral monotherapy to beat platinum-doublet chemotherapy in first-line EGFR exon20ins NSCLC (WU-KONG28); and a JAMA NMA of 716 trials finds ARB+CCB is the best-tolerated antihypertensive combination — outperforming even placebo on net side-effect burden.

PubMed Top Medical Papers29/05/2026, 22:23:35

Five papers worth your time — May 28–29, 2026

Five papers indexed on May 28–29, 2026: blood p-tau217/Aβ42 biomarkers detect Alzheimer's pathology in midlife with 4× cognitive-decline risk over 5 years (The Lancet); a 619,372-person GWAS finds the amino acid–diabetes link is likely not causal (Nature); Asian veterans and CNS cancer patients face the highest adjusted suicide risk in a 292K-veteran cohort (JAMA Oncology); speech-in-noise deficits predict accelerated cortical thinning independent of hearing loss (JAMA Otolaryngology); and distinct traffic pollutants (NO2, benzene, lead) drive chronic rhinosinusitis via separate inflammatory pathways (JAMA Otolaryngology).

PubMed Top Medical Papers28/05/2026, 22:25:23

Five papers — May 27–28, 2026

BioVAT iPSC-derived heart muscle patches show 4.5 mm wall thickening and 3.9 pp LVEF gain in NEJM Phase 1/2. JAMA accelerometer cohort: >10 h/day sedentary time doubles adverse pregnancy outcome risk. Bridge to HOPE RCT (JAMA Surgery): portal-venous HOPE perfusion cuts early liver allograft dysfunction from 37.3% to 20.2% across 15 US centers. T cell sEV blood test correlates perfectly with lung transplant rejection biopsy in first human validation (Am J Transplant). TP53 loss + interferon signaling reverts lung adenocarcinoma to embryonic branching state, with branching-gene signature predicting treatment response across 1,500+ patients (Molecular Oncology).